Amber Bio

👥 14 employees💰 Last funded Aug 2023
Pharmaceutical Manufacturing🌐 amber.bio
Website LinkedIn
Amber Bio is a biotechnology company pioneering new gene editing modalities using multi-kilobase edits to reach previously undruggable patient populations. The current paradigm in genetic medicine relies on developing independent therapies for each separate mutation in the patient population. Founded by pioneers in the CRISPR field from leading institutions for gene editing research, the company is developing a first-of-its-kind RNA writing platform capable of editing thousands of diverse mutations across patients with a single product.
3
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
2
United Kingdom
1
Frequently asked questions
Who invested in Amber Bio?
Amber Bio has 3 investors on record on gritt.io.
When did Amber Bio last raise funding?
The most recent investment in Amber Bio recorded on gritt.io was in August 2023.
What industry is Amber Bio in?
Amber Bio operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.